 monotherapi nilutamid pure nonsteroid antiandrogen untreat patient metastat carcinoma prostat italian prostat cancer project total untreat patient metastat carcinoma prostat pure nonsteroid antiandrogen singl agent object respons rate confid interv median progression-fre surviv median surviv month patient progress antiandrogen addit object respons second-lin endocrin treatment drug patient treatment moder gastrointestin symptom third patient decreas adapt electroretinogram dark adapt test presenc function damag visual complaint patient cessat therapi frequent side effect slight nausea patient alcohol intoler nonsignific increas testosteron level month treatment level stabl half activ men mainten libido sexual potenc treatment signific increas hemoglobin long term occurr trophic effect androgen erythropoiesi result nilutamid singl agent accept toxic moder activ sexual interest discret number case whether monotherapi nonsteroid antiandrogen valid option palliat advanc diseas compar prospect trial